---
title: "Inhibrx Biosciences expands Oxford Finance loan facility to USD 500 million"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292910575.md"
description: "Inhibrx Biosciences amended its loan agreement with Oxford Finance, expanding the credit facility to USD 500 million. The expansion includes a new USD 325 million tranche, with USD 100 million funded immediately as a Term C Loan and up to USD 225 million available as a Term D Loan. Lenders received warrants for 21,457 shares at a strike price of USD 93.21."
datetime: "2026-07-16T13:04:37.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292910575.md)
  - [en](https://longbridge.com/en/news/292910575.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292910575.md)
generator: "portal-rs"
---

# Inhibrx Biosciences expands Oxford Finance loan facility to USD 500 million

-   Inhibrx Biosciences entered a second amendment to its loan and security agreement with Oxford Finance, expanding the credit facility to USD 500 million. \* New tranche adds up to USD 325 million; USD 100 million funded at signing as a Term C Loan. \* Up to USD 225 million more available as a Term D Loan in USD 50 million minimum draws, subject to lenders’ discretion. \* Company had already drawn USD 175 million under the facility before the amendment. \* Lenders received warrants for 21,457 shares at a USD 93.21 strike price, equal to 2% of the Term C Loan value. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inhibrx Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA05812) on July 16, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [INBX.US](https://longbridge.com/en/quote/INBX.US.md)

## Related News & Research

- [Inhibrx Biosciences (NASDAQ:INBX) Earns Buy Rating from Analysts at HC Wainwright](https://longbridge.com/en/news/296785368.md)
- [Should FDA Review of Ozekibart and INBRX-106 Data Milestones Require Action From Inhibrx (INBX) Investors?](https://longbridge.com/en/news/296008452.md)
- [Proport Invest secures SEK 750,000 in board-member loans at 15% annual interest](https://longbridge.com/en/news/296758602.md)
- [Lument Finance (LFT) Q2 2026 Earnings Call Transcript](https://longbridge.com/en/news/296563323.md)
- [reAlpha (NASDAQ: AIRE) Completes InstaMortgage Acquisition, Adding Direct Lending Capabilities to Company’s Integrated Platform | AIRE Stock News](https://longbridge.com/en/news/296617611.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**